ALNY vs. ILMN: Alnylam Pharmaceuticals vs. Illumina Stock Comparison

Company Profile

Alnylam Pharmaceuticals (ALNY) and Illumina (ILMN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ALNY is classified in Biotechnology while ILMN is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Illumina (ILMN) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while Alnylam Pharmaceuticals (ALNY) is defensive at 0.45 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Illumina (ILMN) at 32.39% also sits in the top quartile.

Both Alnylam Pharmaceuticals (ALNY) at 52.85% and Illumina (ILMN) at 19.72% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Illumina (ILMN) at 20.02% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Illumina (ILMN) at -0.66% is in the bottom quartile, showing a clear gap in revenue momentum.

Neither Alnylam Pharmaceuticals (ALNY) nor Illumina (ILMN) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Both Alnylam Pharmaceuticals (ALNY) at 2.48 and Illumina (ILMN) at 2.63 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

Both Alnylam Pharmaceuticals (ALNY) at 0.83 and Illumina (ILMN) at 0.74 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

Financial Strength Metrics

Dividends

Neither Alnylam Pharmaceuticals (ALNY) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Alnylam Pharmaceuticals (ALNY) nor Illumina (ILMN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Illumina (ILMN) at 36.68 is closer to its industry’s usual earnings multiple — a discount for ALNY, though growth and earnings durability still matter.

On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Illumina (ILMN) at 7.10 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

Alnylam Pharmaceuticals (ALNY) at 5.79 is valued about in line with its industry on P/B ratio, while Illumina (ILMN) at 10.30 carries an above-peer premium to book — ILMN is pricier on assets.

Valuation Metrics